cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cytosorbents Corp
9 own
12 watching
Current Price
$1.05
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
103M
52-Week High
52-Week High
3.85000
52-Week Low
52-Week Low
0.70000
Average Volume
Average Volume
0.04M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization103M
icon52-Week High3.85000
icon52-Week Low0.70000
iconAverage Volume0.04M
iconDividend Yield--
iconP/E Ratio--
What does the Cytosorbents Corp do?
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.
Read More
How much money does Cytosorbents Corp make?
News & Events about Cytosorbents Corp.
Globe Newswire
1 year ago
CytoSorbents Hosts Research Symposium at ISICEM CytoSorbents Highlights New Clinical Data from Current Studies at the 2023 International Symposium on Intensive Care & Emergency Medicine PRINCETON, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation(NASDAQ: CTSO), a leader in the ...
PR Newswire
1 year ago
CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference PR Newswire PRINCETON, N.J., Feb. 27, 2023 PRINCETON, N.J., Feb. 27, 2023 /PRNewswire/ -- CytoSorbents Corporation(NASDAQ: CTSO), a leader in the treatment...
PR Newswire
1 year ago
CytoSorbents to Report Fiscal 2022 Operating and Financial Results CytoSorbents to Report Fiscal 2022 Operating and Financial Results PR Newswire MONMOUTH JUNCTION, N.J., Feb. 24, 2023 MONMOUTH JUNCTION, N.J., Feb. 24, 2023 /PRNewswire/ -- CytoSorbents Corporation(NASDAQ: CTSO), a leader in the...
Ticker Report
1 year ago
StockNews.com lowered shares of Cytosorbents (NASDAQ:CTSO Get Rating) from a hold rating to a sell rating in a research note released on Thursday. Separately, HC Wainwright decreased their target price on Cytosorbents from $9.00 to $5.50 and set a buy rating for the company in a research ...
Ticker Report
1 year ago
StockNews.com upgraded shares of Cytosorbents (NASDAQ:CTSO Get Rating) from a sell rating to a hold rating in a research report report published on Thursday morning. Separately, HC Wainwright cut their price objective on Cytosorbents from $9.00 to $5.50 and set a buy rating on the stock in a...
Frequently Asked Questions
Frequently Asked Questions
What is Cytosorbents Corp share price today?
plus_minus_icon
Can Indians buy Cytosorbents Corp shares?
plus_minus_icon
How can I buy Cytosorbents Corp shares from India?
plus_minus_icon
Can Fractional shares of Cytosorbents Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Cytosorbents Corp stocks?
plus_minus_icon
What is today’s traded volume of Cytosorbents Corp?
plus_minus_icon
What is today’s market capitalisation of Cytosorbents Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Cytosorbents Corp?
plus_minus_icon
What percentage is Cytosorbents Corp down from its 52-Week High?
plus_minus_icon
What percentage is Cytosorbents Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$1.05
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00